Skip to main content
Caplight Logo









SaNOtize Research & Development Corp.

SaNOtize Research & Development Corp.

Private
VancouverHealthcare & Life Scienceshttps://sanotize.com/

Last Round

Series B

Aug 24, 2022

Total Funding Raised

$24.45M

Company Overview

SaNOtize Research & Development Corp. is a pharmaceutical company that develops and commercializes nitric oxide-based antimicrobial therapeutics for the treatment and prevention of viral, bacterial, and fungal infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

nitric oxide nasal sprayNONSantimicrobial therapyrespiratory treatmentantiviral nasal spraynitric oxide geltopical antimicrobialmedical devicebiotechpharmaceutical licensingover-the-counter medicineOTCviral load reductionrespiratory health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SaNOtize Research & Development Corp. Comparables

Compare SaNOtize Research & Development Corp. with similar companies based on industry and business-model similarity.

SaNOtize Research & Development Corp. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Enzymatica
79%
Firebrick Pharma Ltd
78%
Birmingham Biotech Ltd
78%

SaNOtize Research & Development Corp. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 24, 2022
VC RoundMar 12, 2020
SeedFeb 1, 2019

Key People

Founding team and executive leadership

Mikael Svensson

Chief Executive Officer

Executive Team

John Sharp

Chief Financial Officer

Executive Team

SaNOtize Research & Development Corp. Investors

Notable investors and investment history

SaNOtize Research & Development Corp. investors
InvestorRounds
Horizons VenturesSeries B
Agricultural Bank of China InternationalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2025

    Grew 20% QoQ, from 20 to 24 employees.

  • Feb 1, 2019

    $450K raised in Seed round.

SaNOtize Research & Development Corp. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SaNOtize Research & Development Corp. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SaNOtize Research & Development Corp.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersVancouver
Employee Range18
Year Founded2017
Last FundingAug 24, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?